Jade Biosciences Inc’s recently made public that its Shareholder Atlas Venture Fund XII, L.P. acquired Company’s shares for reported $0.3 million on Jun 25 ’25. In the deal valued at $10.48 per share,28,977 shares were bought.
Then, Atlas Venture Associates XII, bought 235 shares, generating $2,463 in total proceeds.
Before that, Atlas Venture Fund XII, L.P. bought 16,132 shares. Jade Biosciences Inc shares valued at $159,223 were divested by the Shareholder at a price of $9.87 per share.
Jefferies initiated its Jade Biosciences Inc [JBIO] rating to a Buy in a research note published on July 14, 2025; the price target was $16. A number of analysts have revised their coverage, including Guggenheim’s analysts, who increased its forecast for the stock in mid June from “a Neutral” to “a Buy”. Wedbush began covering JBIO with “an Outperform” recommendation on May 07, 2025. Stifel started covering the stock on May 05, 2025. It rated JBIO as “a Buy”.
Price Performance Review of JBIO
On Tuesday, Jade Biosciences Inc [NASDAQ:JBIO] saw its stock fall -1.09% to $9.04. Over the last five days, the stock has gained 4.75%. Jade Biosciences Inc shares have risen nearly 24.23% since the year began. Nevertheless, the stocks have fallen -6.71% over the past one year. While a 52-week high of $13.50 was reached on 04/22/25, a 52-week low of $6.57 was recorded on 06/13/25.
Levels Of Support And Resistance For JBIO Stock
The 24-hour chart illustrates a support level at 8.58, which if violated will result in even more drops to 8.12. On the upside, there is a resistance level at 9.44. A further resistance level may holdings at 9.84.
How much short interest is there in Jade Biosciences Inc?
A steep rise in short interest was recorded in Jade Biosciences Inc stocks on 2025-09-15, dropping by -0.16 million shares to a total of 1.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 1.9 million shares. There was a decline of -8.99%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 02, 2025 when TD Cowen began covering the stock and recommended ‘”a Buy”‘ rating along with a $10 price target.
